scholarly journals Immunohistochemical analysis of angiogenesis in invasive ductal breast carcinoma with correlations to clinic pathological factor

2006 ◽  
Vol 63 (7) ◽  
pp. 635-642 ◽  
Author(s):  
Tatjana Ivkovic-Kapicl ◽  
Slavica Knezevic-Usaj ◽  
Milana Panjkovic ◽  
Katarina Mastilovic
Keyword(s):  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Histological Grade ◽  
P53 Protein ◽  
Immunohistochemical Analysis ◽  
Metastatic Potential ◽  
Biological Indicators ◽  
Invasive Ductal Breast Carcinoma ◽  
Large Tumor ◽  
Tumor Phenotype

Background/aim: Angiogenesis is the formation of new vessels from preexisting ones. The aim of our study was to determine the relevance of tumor-induced angiogenesis, its correlation with some of the commonly used clinical, pathological factors and the recent biological indicators, and metastatic potential of the tumor in a series of 120 patients with invasive ductal carcinoma of the breast. Methods. The identification of microvessels was performed immunohistochemically with factor VIII-related antigen. The microvessel count (MVC) was assessed at the invasive front of each carcinoma. The cases were divided into high-and low-microvessel density groups according to an average number of microvessels found in the multiple fields of the most vessel-dense part of each tumor. The nuclear immunohistochemical staining for hormone receptors, and the p53, and the membranous staining for cerbB-2 were evaluated. Results. There were significant correlations between a high MVC and a large tumor size, high histological grade, and c-erbB-2 protein over expression. There was no association between tumor angiogenesis, as assessed by the MVC, and the hormone receptors status, and the p53 protein expression. In the cases with a high MVC, there was a significant number of tumors with lymph node metastases. Conclusion. Our findings showed that a high MVC might point out an aggressive tumor phenotype. This might help to stratify patients for an appropriate therapy on an individual basis and, thus, offer the possibility of a more effectively tailored treatment program.

scholarly journals The influence of aging on pathologic and immunobiologic parameters of invasive ductal breast carcinoma

2006 ◽  
Vol 63 (11) ◽  
pp. 921-927
Author(s):  
Tatjana Ivkovic-Kapicl ◽  
Slavica Knezevic-Usaj ◽  
Milana Panjkovic ◽  
Dejan Nincic ◽  
Katarina Mastilovic
Keyword(s):  
Breast Cancer ◽  
Cancer Biology ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Histological Grade ◽  
Steroid Hormone Receptors ◽  
Axillary Lymph ◽  
Invasive Ductal Breast Carcinoma ◽  
Ki 67 ◽  
Axillary Lymph Node Metastases

Background/Aim. Most human cancers, including breast one, increase in frequency with aging. The aim of this study was to explore the hypothesis that aging also alters breast cancer biology. Methods. The study included 120 women with primary invasive ductal carcinoma of the breast. We correlated the patients age and diagnosis with the commonly used clinical, pathological factors and newer tumor biomarkers. Immunohistochemical staining was conducted for p53, c-erbB-2, Ki-67, estrogen (ER), progesterone (PR) receptors, and angiogenesis. Results. In our study, the patients with axillary lymph node metastases and negative steroid hormone receptors (ER and PR) were significantly younger than the patients with nodal involvement and positive hormone receptors. There was also a significant association between the patients age, diagnosis and angiogenesis. No association was found between the patients age and tumor size, histological grade, p53, c-erbB-2, and Ki-67. Conclusion. The results of our study supported only partially the hypothesis that the breast cancer biology is significantly affected by a patient's age.

scholarly journals Clinical Values of two Novel Estrogen Receptor Signaling Targeted lncRNAs in Invasive ductal breast carcinoma

2020 ◽  
Author(s):  
shahrzad ilbeigi ◽  
Mostafa Davood Abadi Farahani ◽  
Mohammad Rafiee Monjezi ◽  
Farahnaz Farahani ◽  
Abdolreza Daraei ◽  
...  
Keyword(s):  
Ductal Carcinoma ◽  
Histological Grade ◽  
Age At Menarche ◽  
Molecular Heterogeneity ◽  
Invasive Ductal Breast Carcinoma ◽  
Estrogen Receptor Signaling ◽  
Elevated Expression ◽  
Mcf7 Cell Line ◽  
Her 2 ◽  
Molecular Patterns

Abstract Invasive ductal carcinoma (IDC) is the most frequent type of breast cancer (BC) in women, with a high clinical burden due to its high invasive properties. Despite of new data regarding the molecular heterogeneity of invasive cancers is quickly emerging; far less is known about the molecular patterns among cases of IDC. An expanding body of evidence has demonstrated that dysregulation of long noncoding RNAs (lncRNAs) is involved in heterogeneity feature of the BC. In this study, we analyzed the expression levels of two novel lncRNAs LOC100288637 and RP11-48B3 in 51 IDC tissues in comparison with adjacent non-cancerous tissues (ANCTs). And finally, bioinformatic evaluation has been done.The qPCR results showed that LOC100288637 and RP11-48B3 were significantly overexpressed in tumor tissues compared to normal samples (P= 0.0085 and P= 0.0002, respectively). Also, the two lncRNAs were overexpressed in both MDA-MB-231 and MCF-7 BC cell lines, nevertheless, with a higher expression pattern in MDA-MB-231 than MCF7 cell line. Furthermore, LOC100288637 had an elevated expression level in HER-2 positive tumors compared to HER-2 negative tumors (P= 0.031). Interestingly, the lncRNA RP11-48B3.4 was upregulated in IDC subjects with age at menarche <14 compared to patients with age at menarche ≥14 (P= 0.041). It was observed in another result that lncRNA RP11-48B3.4 is significantly upregulated in tumors with a lower histological grade compared to tumor samples with higher grades (P= 0.047). And finally, using bioinformatic evaluation, we found a predicted interaction between RP11-48B3.4 and mRNA Zinc Finger and BTB Domain Containing 10 (ZBTB10).Altogether, our findings suggest that these lncRNAs with potential oncogenic roles involved in pathogenesis of IDC with clinical significance, and thus, they may serve as novel markers for diagnosis and treatment of IDC.

scholarly journals HER-2/neu overexpression in invasive ductal breast cancer: An association with other prognostic and predictive factors

2007 ◽  
Vol 15 (1-2) ◽  
pp. 15-18 ◽  
Author(s):  
Tatjana Ivkovic-Kapicl ◽  
Slavica Knezevic-Usaj ◽  
Milana Panjkovic ◽  
Dragana Ðilas-Ivanovic ◽  
Mileta Golubovic
Keyword(s):  
Breast Cancer ◽  
Hormone Receptors ◽  
Histological Grade ◽  
Lymph Node Status ◽  
Breast Cancers ◽  
Protein Overexpression ◽  
Large Tumor ◽  
Invasive Ductal Breast Cancer ◽  
Ductal Breast Cancer ◽  
Her 2

Background: HER-2/neu is a proto-oncogene that is amplified/overexpressed in 15 to 30% of invasive breast cancers. The purpose of this study was to determine if any relationship exist between HER-2/neu protein overexpression and estrogen receptor (ER), progesterone receptor (PR), grade, size, and lymph node status in female breast cancer. Methods: A total of 100 cases of invasive ductal breast cancer were included in this study. The hormone receptors and HER-2/neu were studied immunohistochemically (IHC). Using the HER-2/neu DAKO scoring system, scores of 0, 1+ and 2+ were defined as negative and 3+ as positive. Results: HER-2/neu protein overexpression was seen in 20 (20%) of cases. HER-2/neu protein overexpression was present in 4 of 52 T1 lesions (8%), in 11 of 37 T2 lesions (30%), in 3 of 6 T3 lesions (50%), and in 2 of 5 T4 lesions (40%), (p<0.05). Protein overexpression was seen in 7 of 17 grade III tumors (41%), and 13 of 61 grade II tumors (21%). Overexpression was not detected in grade I tumors (p<0.01). Of the 20 Her-2/neu positive cases, ER- and PR-negative status was detected in 60% and 70%, respectively. Conclusion: Statistically significant correlation was found between HER-2/neu protein overexpression and large tumor size, high histological grade, and ER-, PR-negativity. There was no correlation with lymphonodal status.

scholarly journals The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms

2021 ◽  
Vol 11 (3) ◽  
pp. 208
Author(s):  
Anna Angelousi ◽  
Georgios Kyriakopoulos ◽  
Fani Athanasouli ◽  
Anastasia Dimitriadi ◽  
Eva Kassi ◽  
...  
Keyword(s):  
Transcriptome Analysis ◽  
Cox Regression ◽  
P53 Protein ◽  
Immunohistochemical Analysis ◽  
Ki 67 ◽  
Diagnosis And Prognosis ◽  
Immunohistochemical Markers ◽  
Small Series ◽  
Morphological Criteria ◽  
Survival And Development

Adrenal cortical carcinoma (ACC) is a rare cancer with poor prognosis that needs to be distinguished from adrenocortical adenomas (ACAs). Although, the recently developed transcriptome analysis seems to be a reliable tool for the differential diagnosis of adrenocortical neoplasms, it is not widely available in clinical practice. We aim to evaluate histological and immunohistochemical markers for the distinction of ACCs from ACAs along with assessing their prognostic role. Clinical data were retrospectively analyzed from 37 patients; 24 archived, formalin-fixed, and paraffin-embedded ACC samples underwent histochemical analysis of reticulin and immunohistochemical analysis of p27, p53, Ki-67 markers and were compared with 13 ACA samples. Weiss and Helsinki scores were also considered. Kaplan−Meier and univariate Cox regression methods were implemented to identify prognostic effects. Altered reticulin pattern, Ki-67% labelling index and overexpression of p53 protein were found to be useful histopathological markers for distinguishing ACAs from ACCs. Among the studied markers, only pathological p53 nuclear protein expression was found to reach statistically significant association with poor survival and development of metastases, although in a small series of patients. In conclusion, altered reticulin pattern and p53/Ki-67 expression are useful markers for distinguishing ACCs from ACAs. Immunohistopathology alone cannot discriminate ACCs with different prognosis and it should be combined with morphological criteria and transcriptome analysis.

Diagnostic Pitfalls Related to Morular Metaplasia in Endometrioid Carcinoma: An Underestimated Issue

Pathobiology ◽  
2021 ◽  
pp. 1-6
Author(s):  
Antonio Travaglino ◽  
Antonio Raffone ◽  
Annarita Gencarelli ◽  
Serena Saracinelli ◽  
Fulvio Zullo ◽  
...  
Keyword(s):  
Patient Management ◽  
Hormone Receptors ◽  
Immunohistochemical Analysis ◽  
Endometrioid Carcinoma ◽  
Rectosigmoid Colon ◽  
Solid Carcinoma ◽  
Colorectal Origin ◽  
A Minor ◽  
Diagnostic Pitfalls

Here, we present a case that highlights the crucial pitfalls related to the presence of morular metaplasia (MM) in endometrioid carcinoma, which are insufficiently recognized in the routine pathology practice. A 45-year-old woman underwent hysterectomy with rectosigmoidectomy due to a 11-cm mass involving uterus, right ovary, and rectosigmoid colon. Histologically, the lesion appeared as a predominantly solid carcinoma with a minor glandular component. Results of the first immunohistochemical analysis suggested a colorectal origin (PAX8-, CK7-, WT1-, hormone receptors-, and CDX2+ in the absence of mucinous features). Subsequent immunohistochemistry (nuclear β-catenin+, CD10+, and low ki67 in the solid areas) supported a diagnosis of endometrioid carcinoma with diffuse MM. This case remarks that morphological and immunohistochemical features of MM may conceal the glandular architecture and the typical immunophenotype of endometrioid carcinomas. Acknowledging the diagnostic issues related to MM appears crucial to avoid misdiagnosis and inappropriate patient management.

scholarly journals Acute appendicitis as an unusual cause of invasive ductal breast carcinoma metastasis

2020 ◽  
Vol 2020 (12) ◽  
Author(s):  
Vincent De Pauw ◽  
Julie Navez ◽  
Stephane Holbrechts ◽  
Jean Lemaitre
Keyword(s):  
Abdominal Pain ◽  
Breast Carcinoma ◽  
Acute Appendicitis ◽  
Ductal Carcinoma ◽  
Hormonal Treatment ◽  
Locoregional Therapy ◽  
Invasive Ductal Breast Carcinoma ◽  
Ductal Breast Carcinoma ◽  
History Of ◽  
Anticancer Treatment

Abstract Acute appendicitis is one of the most common causes of abdominal pain at the emergency room. In rare cases, it can be caused by malignancy, even metastatic lesions from extra-abdominal neoplasia. Herein, we report a case of a 64-year-old female with a history of invasive ductal carcinoma of the breast treated by chemotherapy, surgery, radiotherapy and hormonotherapy, relapsing several years later as a bone and a pleura metastasis successfully cured by locoregional therapy and hormonal treatment. She presented with acute abdominal pain without signs of peritonitis. Abdominal computed tomodensitometry showed sign of appendicitis. Therefore, laparoscopic exploration and appendicectomy was performed. During surgery, multiple peritoneal nodules were found and harvested. Pathology showed metastatic nodules of invasive ductal breast carcinoma, including in the appendicular wall, concluding to peritoneal carcinomatosis. The postoperative course was uneventful, but the patient died 1 year later after refusing anticancer treatment.

scholarly journals High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer

2019 ◽  
Vol 106 (1) ◽  
pp. 64-69
Author(s):  
Massimiliano Gennaro ◽  
Elisabetta Meneghini ◽  
Paolo Baili ◽  
Sara Bravaccini ◽  
Annalisa Curcio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Active Surveillance ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Tumor Grade ◽  
Receptor Expression ◽  
Invasive Cancer ◽  
Her2 Positive ◽  
Hormone Receptor Expression ◽  
High Consistency

Background: Ductal carcinoma in situ (DCIS) is considered a morphologic precursor of invasive cancer and is often treated with adjuvant whole-breast irradiation and endocrine therapy, as if it were an invasive cancer. Our aim was to provide further support for treatment de-escalation or enrollment of such patients in active surveillance trials. Methods: We retrospectively analyzed data on patients with conservatively treated primary DCIS subsequently diagnosed with ipsilateral invasive breast cancer (IBC) at 2 comprehensive breast cancer centers. From their merged databases, we identified 50 cases with full details on tumor grade, hormone receptor expression, and HER2 amplification, for both the primary DCIS and the corresponding IBC, and we assessed the similarities and differences between the two. Results: Distributions of hormone receptors were similar in primary DCIS and IBC, while high-grade and HER2-positive status was less common in IBC than in primary DCIS. The positivity for estrogen receptors (ER) and well-differentiated or moderately differentiated morphology in the primary DCIS persisted in 90% of the matching IBC. Changes in progesterone receptor expression were slightly more common than those in ER expression. Overall consistency for the luminal-like receptors subtype was found in 90% of cases. Conclusion: The high consistency between the features of primary DCIS and those of subsequent IBC (in the rare but not negligible cases of local failure) should be borne in mind when considering the therapeutic options. Treatment de-escalation and accrual of patients for active surveillance trials could be appropriate for luminal-like precursors.

scholarly journals Unusual Occurrence of Rare Lipid-Rich Carcinoma and Conventional Invasive Ductal Carcinoma in the One Breast: Case Report

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Katarina Machalekova ◽  
Karol Kajo ◽  
Marian Bencat
Keyword(s):  
Lymph Nodes ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Frozen Section ◽  
Histological Grade ◽  
Resection Margins ◽  
Axillary Lymph Nodes ◽  
Positive Staining ◽  
Axillary Lymph ◽  
Palpable Mass

A 56-year-old woman noticed a palpable mass in her left breast during self-examination. Patient was admitted to our hospital and malignant bifocal tumour was diagnosed by ultrasonography, digital mammography, magnetic resonance, and core-cut biopsy. The patient underwent planned conservative surgery (biquadrantectomy) with a sentinel node examination, but after results of the frozen section with positive resection margins and positive sentinel lymph nodes subsequent mastectomy with axillary lymph node dissection were realized. Histology in the resection specimen revealed two isolated and distinct tumours. One of the lesions represented conventional invasive ductal carcinoma of histological grade 3, and the second tumour was evaluated as invasive lipid-rich carcinoma, containing tumour cells with clear and foamy cytoplasm. Lipids in neoplastic cells were detected by Oil Red O staining and ultrastructural examination. Immunohistochemical analysis of both carcinomas was almost identical with negative steroid receptors, positive staining of HER-2, and p53 and with high proliferation activity (Ki-67). Mastectomy specimen contained residual foci of invasive ductal carcinoma and dissected axillary lymph nodes were free of metastasis. Patient underwent first cycles of chemotherapy with paclitaxel and Herceptin together with local radiotherapy and two month after surgery is without any evidence of the disease.

scholarly journals NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry

2009 ◽  
Vol 7 (Suppl_6) ◽  
pp. S-1-S-21 ◽  
Author(s):  
D. Craig Allred ◽  
Robert W. Carlson ◽  
Donald A. Berry ◽  
Harold J. Burstein ◽  
Stephen B. Edge ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Invasive Breast Cancer ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Task Force ◽  
Strong Predictor ◽  
Surgical Oncology ◽  
Task Force Report

The NCCN Task Force on Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry was convened to critically evaluate the extent to which the presence of the estrogen receptor (ER) and progesterone receptor (PgR) biomarkers in breast cancer serve as prognostic and predictive factors in the adjuvant and metastatic settings, and the ability of immunohistochemical (IHC) detection of ER and PgR to provide an accurate assessment of the expression of these biomarkers in breast cancer tumor tissue. The task force is a multidisciplinary panel of 13 experts in breast cancer who are affiliated with NCCN member institutions and represent the disciplines of pathology, medical oncology, radiation oncology, surgical oncology, and biostatistics. The main overall conclusions of the task force are ER is a strong predictor of response to endocrine therapy; ER status of all samples of invasive breast cancer or ductal carcinoma in situ (DCIS) should be evaluated by IHC; IHC measurements of PgR, although not as important clinically as ER, can provide useful information and should also be performed on all samples of invasive breast cancer or DCIS; IHC is the main testing strategy for evaluating ER and PgR in breast cancer and priority should be given to improve the quality of IHC testing methodologies; all laboratories performing IHC assays of ER and PgR should undertake formal validation studies to show both technical and clinical validation of the assay in use; and all laboratories performing IHC assays of hormone receptors in breast cancer should follow additional quality control and assurance measures as outlined in the upcoming guidelines from the American Society of Clinical Oncology and College of American Pathologists.

Sign in / Sign up

Export Citation Format

Share Document